Explorez tous les épisodes du podcast BioBiz Buzz
| Titre | Date | Durée | |
|---|---|---|---|
| Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation | 02 mai 2025 | 00:23:29 | |
In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), aiming to reverse pathological remodeling and prevent thrombosis-without the bleeding risks of traditional therapies. Sörensen discusses the company’s strategic pivot to rare diseases, the science behind their innovative pipeline, and the impact of recent SEK250 million financing on accelerating clinical programs. The conversation also highlights Cereno’s approach to partnerships, regulatory milestones, and the transformative potential of targeting gene expression in cardiovascular drug development. Tune in for a deep dive into the future of disease-modifying therapies and the milestones shaping Cereno’s journey in 2025 ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Bluesky | |||
| Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment | 02 mai 2025 | 00:14:23 | |
This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe, CEO of Dicot Pharma, who discusses the company’s innovative drug candidate, LIB-01. Unlike conventional therapies, LIB-01 introduces a novel mechanism of action and offers a significantly longer efficacy window, 28 days after a brief 3-day dosing according to exploratory data in the phase 1 trial, potentially transforming the standard of care for both ED and PE. Trampe shares insights on the drug’s clinical progress, the company’s strategic partnerships, and efforts to reduce the stigma surrounding sexual health. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Bluesky | |||
| CRISPR Unleashed: How Caszyme Is Redefining the Future of Gene Editing | 01 mai 2025 | 00:19:54 | |
This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology. Your host Mike Ward explores how Caszyme is expanding the boundaries of gene editing through novel enzyme discovery, delivery optimization, and strategic collaborations, enabling breakthroughs in therapeutics, diagnostics, and sustainable agriculture. Dr. Paule discusses Caszyme’s unique approach to engineering smaller, more versatile Cas enzymes, their impact on treating genetic diseases, and the challenges of translating cutting-edge science into clinical and commercial success. The conversation also addresses the importance of diversity in biotech leadership and Caszyme’s vision for a more inclusive and sustainable future, highlighting the transformative potential and ongoing challenges of the CRISPR revolution. ● Feedback ● Subscribe (Get notified when new episodes are available. NO marketing!) ● Bluesky | |||